Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study
- PMID: 21788760
- PMCID: PMC3634369
- DOI: 10.1097/MPG.0b013e31821d6cfd
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study
Abstract
Background: The spectrum and severity of idiosyncratic drug-induced liver injury (DILI) in children are not well established.
Patients and methods: The DILIN (Drug-Induced Liver Injury Network) Prospective Study is a longitudinal multicenter study designed to determine the etiologies, risk factors, and outcomes of suspected DILI. Between September 2004 and September 2009, 30 children ages 2 to 18 years with suspected DILI who met eligibility criteria were enrolled and studied for at least 6 months.
Results: Mean age was 14 years; 70% were girls. Antimicrobial (50%) and central nervous system agents (40%) were the most commonly implicated drug classes, with minocycline (4), isoniazid (3), azithromycin (3), atomoxetine (3), and lamotrigine (3) the leading agents. Median time from drug initiation to symptom onset was 32 days. Peak (median) liver chemistries were aspartate aminotransferase 503 U/L, alanine aminotransferase 727 U/L, alkaline phosphatase 331 U/L, and total bilirubin 3.9 mg/dL. Autoantibodies were common (64%). Liver injury pattern was hepatocellular 78%, cholestatic 13%, and mixed 9%. The DILI episode was scored: mild 32%, moderate 44%, severe 20%, and fatal (within 6 months) 4%. Causality assessment was definite 36%, very likely 36%, probable 16%, possible 8%, and unlikely 4%. Seven percent had persistent liver test abnormalities at 6-month follow-up suggesting chronic DILI. Liver biopsies from 12 children most frequently demonstrated chronic hepatitis or bile duct injury.
Conclusions: Idiosyncratic DILI in children is most commonly caused by antimicrobial or central nervous system agents and usually presents with a hepatocellular injury pattern. The majority of patients recover, but morbidity and infrequent mortality are seen.
Conflict of interest statement
Dr Kleiner and Dr Gu report no conflicts of interest.
Figures
References
-
- Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731–9. - PubMed
-
- Lim JR, Faught PR, Chalasani NP, et al. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr. 2006;148:831–4. - PubMed
-
- Mecarelli O, Pulitano P, Mingoia M, et al. Acute hepatitis associated with lamotrigine and managed with the molecular adsorbents recirculating system (MARS) Epilepsia. 2005;46:1687–9. - PubMed
-
- Goldstein NS, Bayati N, Silverman AL, et al. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol. 2000;114:591–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 DK065211/DK/NIDDK NIH HHS/United States
- 1U01DK065238/DK/NIDDK NIH HHS/United States
- 1U01DK065021/DK/NIDDK NIH HHS/United States
- U01 DK065201/DK/NIDDK NIH HHS/United States
- U01 DK065238/DK/NIDDK NIH HHS/United States
- UL1 TR001108/TR/NCATS NIH HHS/United States
- U01 DK065193/DK/NIDDK NIH HHS/United States
- 1U01DK065201/DK/NIDDK NIH HHS/United States
- U01 DK065176/DK/NIDDK NIH HHS/United States
- UL1 RR025747/RR/NCRR NIH HHS/United States
- UL1 RR024150/RR/NCRR NIH HHS/United States
- UL1 RR024134/RR/NCRR NIH HHS/United States
- 1U01DK065193/DK/NIDDK NIH HHS/United States
- 1U01DK065211/DK/NIDDK NIH HHS/United States
- UL1 RR025761/RR/NCRR NIH HHS/United States
- UL1 RR024982/RR/NCRR NIH HHS/United States
- 1U01DK065176/DK/NIDDK NIH HHS/United States
- UL1 RR024986/RR/NCRR NIH HHS/United States
- 1U01DK065184/DK/NIDDK NIH HHS/United States
- U01 DK065184/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
